March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Pharmaceutical Treatment of Orbital Vascular Malformation: Intralesional Injection of Pingyangmycin
Author Affiliations & Notes
  • Han Yue
    Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Jiang Qian
    Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Jie Guo
    Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Yifei Yuan
    Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Rui Zhang
    Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Qin Ge
    Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Footnotes
    Commercial Relationships  Han Yue, None; Jiang Qian, None; Jie Guo, None; Yifei Yuan, None; Rui Zhang, None; Qin Ge, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Han Yue, Jiang Qian, Jie Guo, Yifei Yuan, Rui Zhang, Qin Ge; Pharmaceutical Treatment of Orbital Vascular Malformation: Intralesional Injection of Pingyangmycin. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1256.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the efficiency and safety of intralesional injection of Pingyangmycin for the treatment of orbital vascular malformations.

 
Methods:
 

This study reported 13 patients received intralesional injection of Pingyangmycin at Eye and ENT Hospital of Fudan University in China. CT scan with graphic processing software was applied to calculate the volumes of lesions before and after the injection to demonstrate the change of volumes quantificationally.

 
Results:
 

In the 13 patients, there were 5 (38.5%) male and 8 (61.5%) female, with the average age of 36.1 years (range, 16-58 years). Six (46.2%) patients were dignosised as venous malformation, six (46.2%) as cavernous hemangioma and one (7.7%) as lymphangioma. Proptosis and eyelid swelling were the most common presenting signs. The mean injection dose of Pingyangmycin was 4.2 mg (range, 2-6 mg). The preoperative volume of lesions was 4.4 cm3 on average (range, 1.6-8.8 cm3), and reduced to 1.5 cm3 (range, 0.2-6.6 cm3) after Pingyangmycin treatment at a time interval of 6.6 months on average (range, 1.6-21.4 months); and the mean percentage of the volume reduction was 68.8% (range, 24.5-88.3%). Statistically, the volumes of lesion diminished significantly (Matched t-Test, t=6.7, P<0.001). And no one showed local or systemic side effects during follow-ups (mean, 11.5 months; range, 2.3-23.4 months).

 
Conclusions:
 

Intralesional injection of Pingyangmycin for the treatment of orbital vascular malformation is safe and effective.

 
Keywords: orbit 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×